Select Topic:
Browse by Series:

Treating mCRPC with Newer Hormonal Agents

Panelists: Philippa J. Cheetham, MD, Stonybrook University;Raoul S. Concepcion, MD, Urology Associates, PC; Kenneth M. Kernen, MD, Michigan Urology;
Published: Monday, Sep 29, 2014

For High-Definition, Click
Abiraterone, an androgen synthesis inhibitor, is used with caution by urologists because it needs to be given with prednisone, comments Kenneth Kernen, MD. Monitoring patients appropriately and counseling patients regarding the importance of compliance with oral therapy are important when using newer agents such as abiraterone, notes Kernen. Neal Shore, MD, adds that urologists were reluctant to use zoledronic acid when it was approved because it was administered intravenously. The team approach to the treatment of mCRPC has evolved along with the introduction of newer therapies, and Shore notes that healthcare providers, physician assistants, nurses, and administrative staff all play a role in the administration of newer drugs.

Philippa Cheetham, MD, discusses urologists’ fear of prescribing the androgen receptor inhibitor enzalutamide due to the risk of seizure; recent ASCO data have shown that the risk of seizure with enzalutamide is low. Michael Williams, MD, states that the best approach with newer agents is for everyone involved in patient care to be well trained and to work together as a team when treating patients with mCRPC.

Slider Left
Slider Right
For High-Definition, Click
Abiraterone, an androgen synthesis inhibitor, is used with caution by urologists because it needs to be given with prednisone, comments Kenneth Kernen, MD. Monitoring patients appropriately and counseling patients regarding the importance of compliance with oral therapy are important when using newer agents such as abiraterone, notes Kernen. Neal Shore, MD, adds that urologists were reluctant to use zoledronic acid when it was approved because it was administered intravenously. The team approach to the treatment of mCRPC has evolved along with the introduction of newer therapies, and Shore notes that healthcare providers, physician assistants, nurses, and administrative staff all play a role in the administration of newer drugs.

Philippa Cheetham, MD, discusses urologists’ fear of prescribing the androgen receptor inhibitor enzalutamide due to the risk of seizure; recent ASCO data have shown that the risk of seizure with enzalutamide is low. Michael Williams, MD, states that the best approach with newer agents is for everyone involved in patient care to be well trained and to work together as a team when treating patients with mCRPC.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x